Novartis Pharmaceuticals Corp. v. Torrent Pharma Inc., decided 10 Jan 25

This case centered on the validity of Novartis's patent for Entresto, a heart failure medication. The lower court found the patent invalid for lack of written description, but the appeals court reversed this decision, finding the patent adequately described the claimed invention. The appeals court upheld the lower court's findings that the patent claims were not obvious or lacking enablement. The dispute involved the construction of the claim term "administered in combination," impacting whether the patent covered a complexed or uncomplexed form of the drug.